The latest Investing Matters Podcast episode with multi-award-winning fund manager and international bestselling author Lee Freeman-Shor has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: -0.50 (-3.51%)
Spread: 0.50 (3.704%)
Open: 14.25
High: 14.50
Low: 13.75
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

2nd UPDATE: Cloudbuy, ANGLE Latest To Detail Unusual Stock-For-Loan Deals

Wed, 12th Nov 2014 13:39

LONDON (Alliance News) - Cloudbuy PLC and ANGLE PLC Wednesday clarified recent deals in which top executives used shares as security for loans from Equities First Holdings LLC to fund house moves, as scrutiny of unusual share transactions involving the US stock loan company increased.

The news comes as the Daily Mail reported that the UK's Financial Conduct Authority is set to investigate a series of announcements made by Quindell PLC regarding a stock-for-loan deal done by three of its executives with Equity First Holdings.

The FCA declined to comment to Alliance News. The London Stock Exchange wasn't immediately available for comment.

The mechanics of the loans being provided by Equities First are the same in each case: it takes shares as a security for a loan and takes a percentage of the value as well as a financing arrangement fee. Equities First can legally do as it pleases with the shares, but pledges to hold them and not use them for short selling. The loanees are required to buy back the shares once the loans mature.

In a statement, ANGLE said it wanted to provide more information about a deal Chief Executive Andrew Newland did on October 21, transferring up to 3.5 million shares to Equity First as security for a loan facility in connection with moving house.

ANGLE said that under the sale and repurchase agreement, Newland transferred the legal and beneficial interest in 1.35 million shares to Equities First at a discount. He got a payment equal to 62% of the three-day average mid-price per share less a financing arrangement fee of 2%.

He's obliged to buy back the shares at 67% of the starting market price once the loan reaches maturity. However, he may also have to cover margin calls for big fluctuations in the stock price: if the value of the transferred shares falls to 49.6% or less of the starting market price, Newland will have to stump up more shares or cash to cover the difference.

The deal means Newland now holds just over 5.7 million shares with voting rights, or 12.61% of the company's share issue, although his overall share interest is nearly 7.1 million shares, a 15.59% stake.

"Andrew has entered into this finance arrangement to bridge the purchase and renovation of a new house. Andrew believes strongly in the future value of ANGLE and does not want to sell his shares into the market. This facility enables him to return to his original position once the facility is repaid," ANGLE Chairman Garth Selvey said in the statement.

CloudBuy, meanwhile, said Chairman Ronald Duncan had pledged up to 4.5 million shares to Equities First in return for a loan that is also partly being used for a house move.

It said Duncan transferred 2.25 million shares in return for GBP533,490.30, which he used to buy and rennovate his new house, and he intends to use the rest of the loan by transferring a further 2.25 million to Equities First. It didn't say what the balance will be used for.

Cloudbuy didn't set out the exact terms of the transfer, but said that Duncan has agreed to buy back all the transferred shares at 27.16 pence each. The deal also includes a margin call whereby if the value of the transferred shares falls below 19.5 pence, Duncan will have to either terminate the deal or put up more shares or cash.

"In order to minimise disruption around the move, we put in place a facility which would allow us to remain in our existing house whilst the renovation was carried out, following this we will sell the existing house and release the equity," Duncan said in a statement.

Duncan and his family now have hold just over 18.8 million voting shares in cloudBuy, about 15.7% of the company's share issue, and this will fall to nearly 16.6 million shares when he transfers the second tranche of the shares for the loan. He still has a total interest in nearly 21.1 million shares, or a 17.6% stake.

ANGLE shares were down 8.6% at 75.14 pence midday Wednesday, while cloudBuy was down 6.5% at 33.66 pence.

Earlier this week, Quindell was forced to explain a recent share dealing by three of its directors that also involved putting up shares as security in return for a loan from Equities First. In this case, a portion of each loan was used to buy more Quindell shares.

On November 5, Chairman Robert Terry, Finance Director Laurence Moorse and Non-Executive Director Steve Scott bought nearly 1.6 million shares in total, using funds from loans provided by Equities First, which describes itself as "a pioneer in stock loans". A company controlled by Scott, Bickleigh Ridge Ltd, also bought 175,000 shares using the same mechanism, it was announced two days later.

In this case, Equities First had paid a sum equal to 67% of the three-day average market value per share less a financing arrangement fee of 3% for the shares transferred as security for the loan. Terry transferred 8.85 million shares, Moorse 200,000 shares and Scott 1.4 million.

The Quindell directors may also be required to meet margin calls if the Quindell share price fluctuates wildly. If the share price falls to 80% or less of the value at the time they were transferred to Equities First, then they'll have to transfer more of their holdings to the US company or to provide cash to satisfy margin calls, Quindell said.

Terry used GBP1.2 million of the GBP7.5 million he was loaned to buy 1 million more Quindell shares, while Moorse used GBP61,500 of his GBP168,714 proceeds to buy 50,000 more shares and Scott used 861,647.50 of his GBP1.1 million loan to buy a further 525,000 shares.

Quindell didn't say what the remaining portions of the loans were bring used for.

Terry has said the directors did the deal because they felt Quindell's shares were undervalued and the board was confident the company would meet its full-year market expectations and its longer-term prospects.

As the Quindell share price slid on the news, Terry subsequently went on to buy 300,000 shares in the open market, and was joined by Chief Executive Robert Fielding. Fielding, who wasn't one of the directors taking part in the loan deal, also reiterated that the purchase signalled his confidence in the company's prospects.

Quindell shares were down a further 8.1% to 69.40 pence Wednesday. The stock has now declined 55% in the past month, and is down 42% since the company gave the additional details about the director loan deals.

A Quindell spokesperson said that the drop was net yet big enough to trigger a margin call on the transferred shares.

Other AIM-listed companies whose directors are known to have engaged with Equities First as part of their share dealings are IQE PLC and Igas Energy PLC. Both these deals were the same as the Quindell deal in that the loans were used to buy more stock in each company.

IQE, which supplies advanced semiconductors wafer products, said on October 14 that Chief Executive Officer Drew Nelson, Chief Financial Officer Phillip Rasmussen and Chief Operating Officer Howard Williams acquired a total of 3.3 million shares in the company with a the help of a loan from Equities First secured with some of their existing holdings.

Meanwhile, IGas Energy PLC said on January 16 that Chief Executive Andrew Austin bought 300,000 shares in the company, funded with a loan from Equities First that was secured by some of his existing holdings.

IQE and IGas were not immediately available for comment.

IQE shares were down 1.0% at 16.58 pence Thursday, and IGas was down 5.3% at 63 pence.

By Steve McGrath, Sam Agini and Hana Stewart-Smith; stevemcgrath@alliancenews.com; @stevemcgrath1

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
22 Apr 2024 16:52

IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide

Angle PLC - Surrey-based medical diagnostics provider - Says it has been granted a European and US patent for its CellKeep slide. "We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions....This is a significant technology advancement for the [circulating tumor cell] liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer," says Chief Executive Officer Andrew Newland. The CellKeep slide was developed by Angle to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells.

Read more
22 Apr 2024 06:59

Angle granted European patent for CellKeep, US patent imminent

(Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US patent application.

Read more
22 Jan 2024 18:03

IN BRIEF: Angle highlights supportive data for DNA analysis tool

Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.

Read more
4 Jan 2024 16:54

LONDON MARKET CLOSE: Stocks up ahead of US nonfarm payrolls

(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data.

Read more
4 Jan 2024 12:19

Angle shares soar following "breakthrough" cancer diagnostics results

(Alliance News) - Angle PLC on Thursday said that "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.

Read more
4 Jan 2024 12:09

LONDON MARKET MIDDAY: Retailers Next and JD Sports bookend FTSE 100

(Alliance News) - Stock prices in London were slightly higher at midday on Thursday, with the FTSE 100 looking set to snap the two-day losing streak it suffered at the start of the year.

Read more
4 Jan 2024 10:43

AIM WINNERS & LOSERS: Angle soars on clinical tests; Likewise sales up

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
4 Jan 2024 08:58

LONDON MARKET OPEN: Next leads buoyant FTSE 100 amid services PMIs

(Alliance News) - Stock prices in London opened up on Thursday, amid a slew of services PMI data, including for the UK, while reacting to the latest data from China.

Read more
4 Jan 2024 07:58

Angle receives 'breakthrough results' from DNA molecular analysis

(Sharecast News) - Liquid biopsy company Angle received "breakthrough results" from DNA molecular analysis of cancer patient blood samples on Thursday, sending its shares skywards as a result.

Read more
2 Jan 2024 09:04

Angle locks in $250,000 contract with Eisai

(Sharecast News) - Liquid biopsy company Angle has locked in a $250,000 contract with global pharmaceutical company Eisai to deliver circulating tumour cell analysis in a pilot study.

Read more
2 Jan 2024 08:51

IN BRIEF: Angle teams with Japan's Eisai in breast cancer drug trial

Angle PLC - Surrey, England-based medical diagnostics - Signs contract with Eisai Inc, part of Tokyo-based pharmaceutical firm Eisai Co Ltd. Under the agreement, the two will engage in a pilot study worth USD250,000 to Angle. Angle will provide circulating-tumour-cells analysis using its Portrait HER2 assay to assess the response of breast cancer patients to Eisai's BB-1701 antibody-drug conjugate. BB-1701 targets HER2, a protein that speeds up the growth of breast cancer cells. Success in the phase two pilot study will offer the possibility for multiple follow-up studies.

Read more
11 Dec 2023 20:44

TRADING UPDATES: Ondine Biomedical raises GBP2.9 million via placing

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
5 Dec 2023 11:50

IN BRIEF: Angle launches diagnostic kit at cancer symposium

Angle PLC - Surrey, England-based medical diagnostics company - Launches its Portrait Plus CTC staining kit at the San Antonio Breast Cancer Symposium, following "extensive" development, optimisation and validation of the kit. Explains that the kit is read-to-use, and designed for the dentification, characterisation and enumeration of epithelial and mesenchymal cancer cells. This includes those undergoing epithelial-to-mesenchymal transition.

Read more
9 Nov 2023 14:29

Angle says build up of revenue slower than hoped; launches test

(Alliance News) - Angle PLC on Thursday said it expects revenue in 2023 to more than double from 2022 as it announced the launch of a new test aimed to support cancer therapy studies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.